5,140
-0.19%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Dongwha Pharm Co
Its shares trade on KRX under the ticker 000020.KS. It has been listed since 24 March 1976. In the fiscal year to 31 December 2025, it reported revenue of ₩496.39bn and net income of ₩8.69bn. At that date it held total assets of ₩642.17bn and shareholders' equity of ₩379.53bn.
Dong Wha Pharm Co., Ltd. engages in the manufacture and sale of pharmaceuticals and medicinal chemicals. The company is headquartered in Seoul, Seoul. The Company’s products consist of ethical drugs, including digestive system remedies, antibiotics, cardiovascular and metabolic disease treatments, non steroidal anti-inflammatory drugs, respiratory remedies, muscle relaxants, nervous system remedies, dermatological remedies and urinary system remedies, and over-the-counter (OTC) drugs, including cold remedies, dental remedies, dermatological remedies, hepatic protectors, nutrients, tonics, topical analgesics, anti-smoking agents and others. The company also provides medicine raw materials, health food and drinks, as well as cosmetics. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 24 Mar 1976
- Website
- dong-wha.co.kr ↗
Leadership
Pay as last reported
- Mr. Do Jun YoonChairman, since 2005
- Mr. Jun Ha YooCo-Chief Executive Officer, Vice President, Director, since 2021
- Mr. Jong Hyeon HanCo-Chief Executive Officer, Director, since 2022
- Mr. Gil Jun YoonVice Chairman, since 2009
- Mr. Yin Ho YoonVice President, Director
- Mr. Yin Deok LeeManaging Director
- Mr. Dae Hui LeeManaging Director
- Mr. Sang Hwi ChoAssistant Managing Director, since 2021
- Mr. Dae Hyeon KimAssistant Managing Director, since 2020
- Mr. Gi Hyeon GilAssistant Managing Director
- Mr. Gyeong Su SungAssistant Managing Director
- Ms. Hyeon Gyeong YoonAssistant Managing Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Dongwha Pharm manufactures ethical drugs including antibiotics and cardiovascular treatments in Seoul, KR.
- Dongwha Pharm offers over-the-counter drugs like cold remedies and dermatological products in the domestic market.
- Dongwha Pharm provides medicine raw materials and health food products to both domestic and overseas markets.
Weaknesses
- Dongwha Pharm's products include digestive system remedies and respiratory treatments in the KR market.
- Dongwha Pharm's OTC drugs feature dental remedies and hepatic protectors for domestic consumers.
- Dongwha Pharm's distribution covers Seoul and overseas markets but lacks specific country details.
Opportunities
- Dongwha Pharm can expand OTC drug sales in the Korean market for cold remedies and tonics.
- Dongwha Pharm may increase overseas distribution of dermatological remedies and anti-smoking agents.
- Dongwha Pharm could grow health food and drink products in the domestic market.
Threats
- Dongwha Pharm faces competition from other pharmaceutical companies in the KR market.
- Dongwha Pharm's overseas market expansion faces challenges in new country regulations.
- Dongwha Pharm must navigate regulatory changes in the Health Care sector for ethical drugs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.